![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Sunesis Pharmaceuticals Inc | NASDAQ:SNSS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.32 | 4.72 | 4.75 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o Rule 13d-1(b)
þ Rule 13d-1(c)
o Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
CUSIP No.
|
867328502
|
13G | Page |
2
|
of |
7
|
Pages |
1 |
NAME OF REPORTING PERSON
Venrock Associates |
||||
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
|
||||
(a) þ 1 | |||||
(b) o | |||||
3 | SEC USE ONLY | ||||
4 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||||
New York, United States | |||||
5 | SOLE VOTING POWER | ||||
NUMBER OF | 0 | ||||
SHARES | 6 | SHARED VOTING POWER | |||
BENEFICIALLY | |||||
OWNED BY | 6,763,880 2 | ||||
EACH | 7 | SOLE DISPOSITIVE POWER | |||
REPORTING | |||||
PERSON | 0 | ||||
WITH | 8 | SHARED DISPOSITIVE POWER | |||
6,763,880 2 | |||||
9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||
6,763,880 2 | |||||
10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* | ||||
o | |||||
11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | ||||
2.5% 3 | |||||
12 | TYPE OF REPORTING PERSON* | ||||
PN |
CUSIP No.
|
867328502
|
13G | Page |
3
|
of |
7
|
Pages |
1 |
NAME OF REPORTING PERSON
Venrock Associates II, L.P. |
||||
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
|
||||
(a) þ 1 | |||||
(b) o | |||||
3 | SEC USE ONLY | ||||
4 | CITIZENSHIP OR PLACE OF ORGANIZATION | ||||
New York, United States | |||||
5 | SOLE VOTING POWER | ||||
NUMBER OF | 0 | ||||
SHARES | 6 | SHARED VOTING POWER | |||
BENEFICIALLY | |||||
OWNED BY | 6,763,880 2 | ||||
EACH | 7 | SOLE DISPOSITIVE POWER | |||
REPORTING | |||||
PERSON | 0 | ||||
WITH | 8 | SHARED DISPOSITIVE POWER | |||
6,763,880 2 | |||||
9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||
6,763,880 2 | |||||
10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* | ||||
o | |||||
11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | ||||
2.5% 3 | |||||
12 | TYPE OF REPORTING PERSON* | ||||
PN |
CUSIP No.
|
867328502
|
13G | Page |
4
|
of |
7
|
Pages |
Item 1(a) |
Name of Issuer:
Sunesis Pharmaceuticals, Inc. |
Item 1(b) |
Address of Issuers Principal Executive Offices:
395 Oyster Point Boulevard Suite 400 South San Francisco, CA 94080 |
Item 2(a) |
Name of Person Filing:
Venrock Associates Venrock Associates II, L.P. |
Item 2(b) | Address of Principal Business Office or, if none, Residence: |
New York Office:
|
Palo Alto Office: | Cambridge Office: | ||
|
||||
530 Fifth Avenue
|
3340 Hillview Avenue | 55 Cambridge Parkway | ||
22nd Floor
|
Palo Alto, CA 94304 | Suite 100 | ||
New York, NY 10036
|
Cambridge, MA 02142 |
Item 2(c) | Citizenship: |
Item 2(d) |
Title of Class of Securities:
Common Stock |
Item 2(e) |
CUSIP Number
867328502 |
Item 3 | Not applicable. |
Item 4 | Ownership |
CUSIP No.
|
867328502
|
13G | Page |
5
|
of |
7
|
Pages |
Item 5 | Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following þ . |
Item 6 |
Ownership of More than Five Percent on Behalf of Another Person:
Not applicable. |
Item 7 |
Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on By the Parent Holding Company:
Not applicable. |
Item 8 | Identification and Classification of Members of the Group: |
Item 9 |
Notice of Dissolution of Group:
Not applicable. |
Item 10 | Certification |
CUSIP No.
|
867328502
|
13G | Page |
6
|
of |
7
|
Pages |
Dated: February 14, 2011 | VENROCK ASSOCIATES | |||
By: | A General Partner | |||
By: | /s/ David L. Stepp | |||
Authorized Signatory | ||||
VENROCK ASSOCIATES II, L.P. | ||||
By: | A General Partner | |||
By: | /s/ David L. Stepp | |||
Authorized Signatory | ||||
CUSIP No.
|
867328502
|
13G | Page |
7
|
of |
7
|
Pages |
Exhibit No. | ||
|
||
99.1
|
Agreement pursuant to Rule 13d-1(k)(1) among Venrock Associates and Venrock Associates II, L.P. |
1 Year Sunesis Pharmaceuticals Chart |
1 Month Sunesis Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions